MicrofluidX (MFX), a UK-based provider of next-generation bioreactors for cell research and manufacturing, has partnered with CCRM, a leader in developing and commercializing regenerative medicine-based technologies and cell and gene therapies, to advance manufacturing of lentivirus (LV) CAR-T cells with their next generation platform, the Cyto Engine.   The project will address the urgent need for higher transduction efficiency, higher homogeneity of the transduced cell population, shorter bi...